DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Subscribe to see Dexcom’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Dexcom is a medical devices company headquartered in San Diego, United States, founded in 1999. It is publicly listed (DXCM) with a market capitalisation of $31.5B. Xcout tracks 35 named people at Dexcom, including Jacob Steven Leach (President, CEO & Director). Xcout recorded 142 job postings from Dexcom in the last 90 days.
29 more named people on record for Dexcom, with roles, board committees and tenure — see the full roster →
Xcout recorded 142 job postings from Dexcom in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Dexcom's hiring signals →
A few of Dexcom's closest competitors — see the full list of competitors and alternatives →
i-SENS is a South Korean global healthcare company specializing in the development and production of blood glucose monitoring systems, continuous glucose monitoring systems, and in-vitro diagnostics.
Apex Biotechnology Corp. is a Taiwanese firm that specializes in the global development, manufacturing, and distribution of medical devices designed for home use, all powered by sophisticated biosensor technology. Their comprehensive product lineup features a variety of personal health monitoring systems, including those for tracking blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1c, and ketone levels. In addition, the company provides self-testing solutions for coagulation and multi-parameter analysis, alongside advanced hemoglobin screening systems. Beyond patient diagnostics, Apex Biotech also offers systems for detecting pesticide residues. The company further extends its services to include digital care management and telehealth platforms. Established in 1997, Apex Biotechnology Corp. operates from its headquarters located in Hsinchu City, Taiwan.
CAIRE Health Holdings, Inc. manufactures and supplies medical oxygen therapy equipment, including portable and stationary oxygen concentrators, liquid oxygen systems, and onsite gas generators. The company also provides cardiorespiratory diagnostics devices to healthcare providers, patients, and commercial applications.
Sphere Medical Holding is a medical device company that develops, manufactures, and sells monitoring and diagnostic equipment for critical care environments. Through its subsidiaries, the company creates products designed for the near real-time measurement of blood gases, electrolytes, glucose, and drug levels.
Biolinq Inc. is headquartered in San Diego, California, and operates as a med-tech company that has been granted De Novo classification for its Biolinq Shine™ product.
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.